'Triall' furthers the blockchain revolution focusing on the medical field whilst operating on robust business and technical foresight. Present world developments including recent Covid-19 pandemic, as well as general progress in the industry warrant Triall's approach. In this overview we will visit:

1. The Solution

2. The Market

3. The Token

4. The Team

Find the Triall.io website here, and it's whitepaper here.

The Solution

Problem statement

It has perhaps taken a fully-fledged pandemic to greater highlight the importance of authentic and convenient data systems within clinical trials as the world has been pressed to respond efficiently to an emergency exacerbated by globalisation. Though the latter, through interconnected communities, and mechanisms such as ease of transport leaves seemingly no corner of the world safe from a disease as contagious as Covid-19, the speed and collaboration with which the emergency is being tackled through vaccination research and clinical trials remains unprecedented in human history.

It is within these modern developments with the backdrop of rapid development in clinical trials, that there is a heightened need for reliable and authentic data, with appropriate oversight from medical professionals.

Covid-19 Total Deaths per Capita. Image Credits: Dan Polansky and contributors.

Key Stakeholders

Pharma Companies, Service Providers including Clinical Trial Managers, Hospitals, and Patients are amongst the main stakeholders. The need to facilitate convenient systems of data collection, sharing, and processing between these groups is at the forefront of an effective battle against global pandemics, and previous or new diseases.

Triall's Approach

Through the use of Blockchain, the project aims to increase the efficiency, trust and regulatory compliance for these key stakeholders. The Triall ecosystem seeks to offer various applications as well as an API infrastructure that will allow the stakeholders to use the technology to tackle their unresolved needs. Amongst these, the project whitepaper has identified:

i. "Fragmentation": That data is kept across various systems with the upshot of inaccessibility from site to site.

ii. "Lack of oversight": A commonly reported issue by medical professionals.

iii. "Recordkeeping failure": That inappropriate or missing records are a hazard to the safety of trial participants and staff, but also increase delays and costs incurred.

iv. "Data integrity issues": That the data may be tampered with or lack authenticity.

It's first part of the ecosystem, Verial eTMF, for clinical document management, has been used since 2019 and provides Triall with a first-mover advantage. This will be complimented by a series of further modular applications that will be interoperable. Ultimately this will create an integrated system rather than a fractured approach where data is kept across isolated systems and applications.

The Market

As aforementioned, the rapid globalisation of this industry is bringing about a need for new solutions allowing for further digitalization and decentralisation - the number of organisations using eTMFs, of which Verial eTMF is also a part of after 2019, in itself quadrupled in the four years prior to it's release.

The future is just as promising with the estimated compound annual growth-rate for the digitalised clinical solutions market sitting at 13.8%. An added advantage that needs to be kept in light is the blockchain-specific operation of Triall's ecosystem. With the latter industry also poised to rapidly grow year-on-year, it is likely that Triall will absorb more growth than just the industrial average.

Furthermore, though there is increased adoption of eClinical solutions, on average, clinical trials use about six different applications which are often solitary and play into the fragmentation issue (i.) but this is something that Triall is set to change with its interoperable applications. It also notes the barriers to SMEs in adopting all-encompassing e-platforms in general at present, including the high cost associated. The whitepaper makes it explicit that they realise this gap in the market, and seek to exploit it.

The Token

The native project token is TRL operating on the ERC-20 (Ethereum) standard, with sound Tokenomics. There will be a total of 175 million tokens available at the initial token offering of which 91 million is to be distributed to the community with 34.6%, 46.2%, and 19.2% of the latter being distributed respectively amongst the presale, treasury and community fund.

The rest of the tokens will be granted to founding team, advisors, existing investors but most importantly, to the growth, acquisition and marketing of the project.

It seems thus that the team is well prepared with a plan and ready for growth in the upcoming years. The token should be a pivotal part in this as with many blockchain projects, and most importantly to the safety of investors, it's smart contracts are audited (find report here) and have received a maximum security score.

The Team

The project does not fall short of knowledge or experience in the slightest, as it has the staggering statistics of, combined, over 100 clinical trials across 30 countries. The latter in particular positions the project well to pursue global implementation and clientele. 

Collectively, they have published more than 250 peer-reviewed papers on pharmaceutical innovation providing a strong backbone of knowledge in  directly relevant field. 

The team is doxxed and available on the whitepaper, but also most importantly occupies a fully equipped array of office positions allowing for the full and professional delivery of Triall.

Disclaimer

This is “a sponsored article written for a bounty reward” written by Bounty0x username @ahmaddaud20.

This is not investment or financial advice, but merely serves informative purpose.